



ESGO 2018 LYON STATE OF THE ART CONFERENCE

# What Have We Learned from 2017 ESGO Congress in Vienna?

---

Murat Gultekin (Turkey), Kamil Zalewski (Poland)

ESGO State of the Art Conference, Patient Seminar, Lyon, France, October 5th – 6th, 2018

**ESGO** | NEW INSIGHTS IN RARE  
GYNAECOLOGICAL MALIGNANCIES  
OCTOBER 4-6, 2018 | LYON, FRANCE  
State of the Art Conference 2018



# Structure of a Presentation

---

- Why do doctors go to conferences
- What is the structure of the ESGO meeting
- Best of ESGO 2017
- Selected presentations



# Do medical conferences have a role to play?

NCBI Resources How To Sign in to NCBI

PubMed US National Library of Medicine National Institutes of Health

Search vulvar cancer

Format: Summary - Sort by: Best Match - Per page: 20 -

Send to - Filters: Manage Filters

Search results

Items: 1 to 20 of 5753

Filters activated: Full text. Clear all to show 9351 items.

Sort by: Best match Most recent

Results by year

Titles with your search term

Prevalence of human papilloma prognostic value in vulvar cancer

In response to Ryzdzewski NR e adjuvant external beam r [Radi

Brief Report on 3-Weekly Paclit Efficacy in Locally r [Gynecol O

1. Rajaram S, Gupta B. Rev Recent Clin Trials. 2015;10(4):282-8. Review. PMID: 26411953 Similar articles

2. Systemic treatment of vulvar cancer. Mahner S, Prieske K, Grimm D, Trillsch F, Prieske S, von Amsberg G, Petersen C, Mueller V, Jaenicke F, Woelber L. Expert Rev Anticancer Ther. 2015 Jun;15(6):629-37. doi: 10.1586/14737140.2015.1037837. Epub 2015 May 21. Review. PMID: 25997120 Similar articles

3. Vulvar cancer surgery. Baiocchi G, Rocha RM. Curr Opin Obstet Gynecol. 2014 Feb;26(1):9-17. doi: 10.1097/GCO.000000000000033. Review. PMID: 24270518



Premium Collection Topics Content Types Events/Courses Contributors Surgical Videos Publications

MULTIPORTAL **EMBASE** Favorites/Navigation history

As you type keywords, suggestions will appear that you can select, then click "search"

From To Search

Protected by US Patents

- Borderline Ovarian Tumors
- Breast tumors
- Cancer and pregnancy
- Cervical cancer : prevention, preinvasive disease
- Endometrial cancer \*
- Fertility sparing management
- General care
- GTD
- Imaging
- Invasive cervical cancer \*
- Medical oncology
- Miscellaneous
- Oncogenetics
- + More

ESGO Advanced Course in Ovarian Cancer Surgery

22-24 MARCH, 2018 - HAMBURG, GERMANY

ESGO 20 INTERNATIONAL MEETING OF THE EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY (ESGO) NOVEMBER 04-07, 2017 VIENNA, AUSTRIA

European Gynaecological Oncology Congress 2017

VIENNA, AUSTRIA 2017

ESGO 2017


Breaking news in the medical treatment of ovarian cancer











**ESGO 20**

INTERNATIONAL MEETING OF  
THE EUROPEAN SOCIETY OF  
GYNAECOLOGICAL ONCOLOGY (ESGO)  
NOVEMBER 04-07, 2017 | VIENNA, AUSTRIA

*European Gynaecological Oncology Congress 2017*



**Plenary Sessions**

Guidelines in gynecological cancers

**Oral Presentations**

Tumour Board Session

**Late Breaking Sessions**

Glass with the Experts Sessions

The Young Gynae Oncologists Program



# ESGO 2017 in numbers



**ESGO** 20

INTERNATIONAL MEETING OF  
THE EUROPEAN SOCIETY OF  
GYNAECOLOGICAL ONCOLOGY (ESGO)  
NOVEMBER 04-07, 2017 | VIENNA, AUSTRIA

*European Gynaecological Oncology Congress 2017*

Best of  
**ESGO** 2017

[www.esgo.org](http://www.esgo.org)

The European Voice of Gynaecological Oncology



# Overview: Best of ESGO 2017

---

- The Best of ESGO 2017 project **highlights the most relevant data** presented at the world's biggest gynecological oncology event in 2017: the 20th International Meeting of the European Society of Gynaecological Oncology.
- The abstracts chosen for this presentation and discussion reflect the **foremost clinical research and strategies** in oncology that will impact our patient care.
- The slides report the **most recent relevant findings in the treatment** of gynecological malignancies presented in Vienna, November 2017.

# List of the studies

- **REFINEMENT OF HIGH-RISK ENDOMETRIAL-CANCER (HR-EC) CLASSIFICATION USING DNA DAMAGE RESPONSE (DDR) BIOMARKERS: A TRANSPORTEC INITIATIVE** - A. Auguste, C. Genestie, M. DeBruyn, J. Adam, F. Drusch4, A. LeFormal-Ensarguex1, P. Pautier5, E. Crosbie, H. MacKay, H. Kitchener, M. Powell, P. Pollock, L. Mileshekin, R. Edmonson, R. Nout, H. Nijman, C. Creutzberg, T. Bosse, A. Leary
- **EXPRESSION OF L1CAM IN CURETTAGE AND HIGH L1CAM LEVEL IN PREOPERATIVE BLOOD SAMPLES PREDICTS LYMPH NODE METASTASES AND POOR OUTCOME IN ENDOMETRIAL CANCER PATIENTS** - I.L. Tangen, R. Kopperud, N. Visser, A. Staff, S. Tingulstad, J. Marcickiewicz, F. Amant, L. Bjørge, J. Pijnenborg, H. Salvesen, H. Werner, J. Trovik, C. Krakstad
- **PRE-SURGICAL METFORMIN IN UTERINE MALIGNANCY-RESULTS OF THE PREMIUM RANDOMISED CONTROLLED TRIALS** - Kitson, Z. Maskell, V. Sivalingam, R. Slade, S. Ali, S. Burns, R. Latheef, K. Gilmour, P. Pemberton, J. Shaw, D. Ryder, H. Kitchener, E. Crosbie
- **CISPLATIN CHEMO-RADIATION VERSUS RADIATION IN FIGO STAGE IIIB SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX (CRACX TRIAL: NCT00193791)** - U. Mahantshetty1, S. Shrivastava1, R. Engineer, S. Chopra, R. Havaladar, V. Hande, R. Kerkar, A. Maheshwari, T. Shylasree, J. Ghosh, J. Bajpai, L. Naidu, S. Gulia, S. Gupta
- **DECISIONAL VALUE OF PRETHERAPEUTIC LAPAROSCOPIC EXTRAPERITONEAL ILIO-PARAAORTIC (EL-PALND) VERSUS PET-CT IN LOCALLY ADVANCED CERVICAL CARCINOMAS (LACC)** - E. Leblanc, F. Narducci, D. Hudry, L. bresson, Y. Borghesi, S. Taieb, A.S. Lemaire, A. Lesoin, H. Gauthier
- **THERAPEUTIC HPV VACCINE-IS IT CLINICALLY USEFUL?** - J. Park, S. Hur, K. Lee, J. Kim, Y. Choi, S. Lee
- **LONG-TERM EFFICACY AND IMMUNOGENICITY OF THE 9-VALENT HUMAN PAPILLOMAVIRUS VACCINE: FINAL ANALYSES OF A DOUBLE-BLIND, RANDOMIZED CLINICAL STUDY** - E. Joura
- **COMPARISON OF MRI, PET-CT, AND FROZEN BIOPSY IN THE EVALUATION OF LYMPH NODE STATUS BEFORE FERTILITY-SPRING RADICAL TRACHELECTOMY IN EARLY STAGE CERVICAL CANCER** - G.W. Lee, S.W. Lee, J.Y. Park, D.Y. Kim, D.S. Suh, J.H. Kim, Y.M. Kim, Y.T. Kim, J.H. Nam
- **PERIOPERATIVE POSITIONING MANAGEMENT IN GYNECOLOGIC CANCER SURGERY: A NATIONAL NOGGO-AGO INTERGROUP SURVEY** - J.K. Wagner, M. Sporkmann, R. Richter, B. Alexander, B. Schmalfeldt, H. Veldink, I. Schrettenbrunner, K. Pietzner, J. Sehouli
- **PROGNOSTIC VALUE OF LYMPH NODE RATIO AND NUMBER OF POSITIVE INGUINAL NODES IN PATIENTS WITH VULVAR CANCER** - S. Polterauer, R. Schwameis, C. Grimm, R. Macuks, S. Iacoponi, K. Zalewski, I. Zapardiel
- **ONCOLOGICAL MANAGEMENT AND PREGNANCY OUTCOMES IN WOMEN DIAGNOSED WITH CANCER DURING PREGNANCY: A 20-YEAR INTERNATIONAL COHORT STUDY OF 1170 PATIENTS** - J. de Haan, M. Verheecke, K. Van Calsteren, B. Van Calster, R. Shmakov, M. Mhallem Gziri, M. Halaska, R. Fruscio, C. Lok, I. Boere, P. Zola, P. Ottevanger, C. de Groot, F. Peccatori, K. Dahl Steffensen, E. Cardonick, E. Polushkina, L. Rob, L. Ceppi, G. Sukhikh, Han, F. Amant
- **SENSITIVITY OF NON-INVASIVE PRENATAL FOR CANCER DETECTION AND TREATMENT MONITORING IN PREGNANT WOMEN** - L. Lenaerts, J. Vermeesch, M. Verheecke, L. Dehaspe, N. Brison, F. Amant
- **HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER** - W.J. van Driel, S. Koole, K. Sikorska, J. Schagen van Leeuwen, H.W. Schreuder, R. Hermans, I. de HIngh, J. van der Velden, H. Arts, L. Massuger, A. Aalbers, V. Verwaal, J. Kieffer, K. van der Vijver, H. van Tinteren, N. Aaronson, G. Sonke
- **ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)** - J.A. Ledermann, A.M. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, A. Dean, N. Colombo, J.I. Weberpals, A. Clamp, G. Scambia, A. Leary, R.W. Holloway, D.M. O'Malley, T. Cameron, L. Maloney, S. Goble, K.K. Lin, J. Sun, H. Giordano, R.L. Coleman
- **LION - LYMPHADENECTOMY IN OVARIAN NEOPLASMS. A PROSPECTIVE RANDOMIZED AGO STUDY GROUP LED GYNECOLOGIC CANCER INTERGROUP TRIAL** - D. Lorusso, J. Sehouli, A. Reuss, I. Vergote, C. Marth, J.W. Kim, F. Raspagliesi, B. Lampe, F. Landoni, W. Meier, D. Cibula, A. Mustea, S. Mahner, I. Runnebaum, B. Schmalfeldt, A. Burges, R. Kimmig, U. Wagner, A. du Bois, P. Harter
- **QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY** - S.P. Blagden, A. Cook, C. Poole, L. Howells, I.A. McNeish, A. Dean, D. Galardo, J.W. Kim, D.M. O'Donnell, J. Hook, E. James, T. Perren, R. Lord, G. Dark, H. Earl, M. Hall, R. Kaplan, J.A. Ledermann, A. Clamp

# List of the studies

- **REFINEMENT OF HIGH-RISK ENDOMETRIAL-CANCER (HR-EC) CLASSIFICATION USING DNA DAMAGE RESPONSE (DDR) BIOMARKERS: A TRANSPORTEC INITIATIVE** - A. Auguste, C. Genestie, M. DeBruyn, J. Adam, F. Drusch4, A. LeFormal-Ensarguex1, P. Pautier5, E. Crosbie, H. MacKay, H. Kitchener, M. Powell, P. Pollock, L. Mileshekin, R. Edmonson, R. Nout, H. Nijman, C. Creutzberg, T. Bosse, A. Leary
- **EXPRESSION OF L1CAM IN CURETTAGE AND HIGH L1CAM LEVEL IN PREOPERATIVE BLOOD SAMPLES PREDICTS LYMPH NODE METASTASES AND POOR OUTCOME IN ENDOMETRIAL CANCER PATIENTS** - I.L. Tangen, R. Kopperud, N. Visser, A. Staff, S. Tingulstad, J. Marcickiewicz, F. Amant, L. Bjørge, J. Pijnenborg, H. Salvesen, H. Werner, J. Trovik, C. Krakstad
- **PRE-SURGICAL METFORMIN IN UTERINE MALIGNANCY-RESULTS OF THE PREMIUM RANDOMISED CONTROLLED TRIALS** - Kitson, Z. Maskell, V. Sivalingam, R. Slade, S. Ali, S. Burns, R. Latheef, K. Gilmour, P. Pemberton, J. Shaw, D. Ryder, H. Kitchener, E. Crosbie
- **CISPLATIN CHEMO-RADIATION VERSUS RADIATION IN FIGO STAGE IIIB SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX (CRACX TRIAL: NCT00193791)** - U. Mahantshetty1, S. Shrivastava1, R. Engineer, S. Chopra, R. Havaladar, V. Hande, R. Kerkar, A. Maheshwari, T. Shylasree, J. Ghosh, J. Bajpai, L. Naidu, S. Gulia, S. Gupta
- **DECISIONAL VALUE OF PRETHERAPEUTIC LAPAROSCOPIC EXTRAPERITONEAL ILIO-PARAAORTIC (EL-PALND) VERSUS PET-CT IN LOCALLY ADVANCED CERVICAL CARCINOMAS (LACC)** - E. Leblanc, F. Narducci, D. Hudry, L. bresson, Y. Borghesi, S. Taieb, A.S. Lemaire, A. Lesoin, H. Gauthier
- **THERAPEUTIC HPV VACCINE-IS IT CLINICALLY USEFUL?** - J. Park, S. Hur, K. Lee, J. Kim, Y. Choi, S. Lee
- **LONG-TERM EFFICACY AND IMMUNOGENICITY OF THE 9-VALENT HUMAN PAPILLOMAVIRUS VACCINE: FINAL ANALYSES OF A DOUBLE-BLIND, RANDOMIZED CLINICAL STUDY** - E. Joura
- **COMPARISON OF MRI, PET-CT, AND FROZEN BIOPSY IN THE EVALUATION OF LYMPH NODE STATUS BEFORE FERTILITY-SPRING RADICAL TRACHELECTOMY IN EARLY STAGE CERVICAL CANCER** - G.W. Lee, S.W. Lee, J.Y. Park, D.Y. Kim, D.S. Suh, J.H. Kim, Y.M. Kim, Y.T. Kim, J.H. Nam
- **PERIOPERATIVE POSITIONING MANAGEMENT IN GYNECOLOGIC CANCER SURGERY: A NATIONAL NOGGO-AGO INTERGROUP SURVEY** - J.K. Wagner, M. Sporkmann, R. Richter, B. Alexander, B. Schmalfeldt, H. Veldink, I. Schrettenbrunner, K. Pietzner, J. Sehouli
- **PROGNOSTIC VALUE OF LYMPH NODE RATIO AND NUMBER OF POSITIVE INGUINAL NODES IN PATIENTS WITH VULVAR CANCER** - S. Polterauer, R. Schwameis, C. Grimm, R. Macuks, S. Iacoponi, K. Zalewski, J. Zapardiel
- **ONCOLOGICAL MANAGEMENT AND PREGNANCY OUTCOMES IN WOMEN DIAGNOSED WITH CANCER DURING PREGNANCY: A 20-YEAR INTERNATIONAL COHORT STUDY OF 1170 PATIENTS** - J. de Haan, M. Verheecke, K. Van Calsteren, B. Van Calster, R. Shmakov, M. Mhallem Gziri, M. Halaska, R. Fruscio, C. Lok, I. Boere, P. Zola, P. Ottevanger, C. de Groot, F. Peccatori, K. Dahl Steffensen, E. Cardonick, E. Polushkina, L. Rob, L. Ceppi, G. Sukhikh, Han, F. Amant
- **SENSITIVITY OF NON-INVASIVE PRENATAL FOR CANCER DETECTION AND TREATMENT MONITORING IN PREGNANT WOMEN** - L. Lenaerts, J. Vermeesch, M. Verheecke, L. Dehaspe, N. Brison, F. Amant
- **HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER** - W.J. van Driel, S. Koole, K. Sikorska, J. Schagen van Leeuwen, H.W. Schreuder, R. Hermans, I. de Hingh, J. van der Velden, H. Arts, L. Massuger, A. Aalbers, V. Verwaal, J. Kieffer, K. van der Vijver, H. van Tinteren, N. Aaronson, G. Sonke
- **ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)** - J.A. Ledermann, A.M. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, A. Dean, N. Colombo, J.I. Weberpals, A. Clamp, G. Scambia, A. Leary, R.W. Holloway, D.M. O'Malley, T. Cameron, L. Maloney, S. Goble, K.K. Lin, J. Sun, H. Giordano, R.L. Coleman
- **LION - LYMPHADENECTOMY IN OVARIAN NEOPLASMS. A PROSPECTIVE RANDOMIZED AGO STUDY GROUP LED GYNECOLOGIC CANCER INTERGROUP TRIAL** - D. Lorusso, J. Sehouli, A. Reuss, I. Vergote, C. Marth, J.W. Kim, F. Raspagliesi, B. Lampe, F. Landoni, W. Meier, D. Cibula, A. Mustea, S. Mahner, I. Runnebaum, B. Schmalfeldt, A. Burges, R. Kimmig, U. Wagner, A. du Bois, P. Harter
- **QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY** - S.P. Blagden, A. Cook, C. Poole, L. Howells, I.A. McNeish, A. Dean, D. Galardo, J.W. Kim, D.M. O'Donnell, J. Hook, E. James, T. Perren, R. Lord, G. Dark, H. Earl, M. Hall, R. Kaplan, J.A. Ledermann, A. Clamp

# **Pre-Surgical Metformin in Uterine Malignancy – Results of The Premium Randomised Controlled Trial**

S. Kitson et al.

**(ESGO7-0375)**

# Introduction –what we know?



Epidemiology/Health Services Research

ORIGINAL ARTICLE

## New Users of Metformin Are at Low Risk of Incident Cancer

A cohort study among people with type 2 diabetes

GILLIAN LIBBY, MSc<sup>1</sup>  
LOUISE A. DONNELLY<sup>1</sup>  
PETER T. DONNAN, PhD<sup>1</sup>

DARIO R. ALESSI, PhD<sup>2</sup>  
ANDREW D. MORRIS, FRCP<sup>3</sup>  
JOSIE M.M. EVANS, PhD<sup>1</sup>

**OBJECTIVE** — The antidiabetic properties of metformin are mediated through its ability to activate the AMP-activated protein kinase (AMPK). Activation of AMPK can suppress tumor formation and inhibit cell growth in addition to lowering blood glucose levels. We tested the hypothesis that metformin reduces the risk of cancer in people with type 2 diabetes.

**RESEARCH DESIGN AND METHODS** — In an observational cohort study using record-linkage databases and based in Tayside, Scotland, U.K., we identified people with type 2 diabetes who were new users of metformin in 1994–2003. We also identified a set of diabetic comparators, individually matched to the metformin users by year of diabetes diagnosis, who had never used metformin. In a survival analysis we calculated hazard ratios for diagnosis of cancer, adjusted for baseline characteristics of the two groups using Cox regression.

**RESULTS** — Cancer was diagnosed among 7.3% of 4,085 metformin users compared with 11.6% of 4,085 comparators, with median times to cancer of 3.5 and 2.6 years, respectively ( $P < 0.001$ ). The unadjusted hazard ratio (95% CI) for cancer was 0.46 (0.40–0.53). After adjusting for sex, age, BMI, A1C, deprivation, smoking, and other drug use, there was still a significantly reduced risk of cancer associated with metformin: 0.63 (0.53–0.75).


**CONCLUSIONS** — These results suggest that metformin use may be associated with a reduced risk of cancer. A randomized trial is needed to assess whether metformin is protective in a population at high risk for cancer.

*Diabetes Care* 32:1620–1625, 2009

increase circulating insulin levels, and hyperinsulinemia may promote carcinogenesis (8). Treatments such as metformin and glitazones reduce insulin resistance, with insulin resistance possibly associated with increased risk of cancer (9). The objective of this study was to test the hypothesis that metformin use is associated with a reduced risk of cancer in people with type 2 diabetes using a national cancer registry to ensure valid diagnoses of cancer with precise dates of diagnosis. We also adjusted results for the effects of exposure to other diabetic drugs.

**RESEARCH DESIGN AND METHODS** — This observational historical cohort study was carried out using anonymous patient data for the resident population of Tayside Health Board in Scotland, U.K. (~400,000 people). Data were provided by the Health Informatics Centre (HIC), University of Dundee, which has developed the record linkage of multiple routinely collected datasets for research. Scottish Care Information—

# Introduction- what we know?



**What is a clinical trial?**  
An introduction for patients and families

The European Voice of Gynaecological Oncology




# Objectives & Methods

## Objectives

- to evaluate the effect of metformin in women with atypical hyperplasia or endometrioid endometrial cancer at a **multi-center, double blind, placebo-controlled trial**.

## Methods



- median duration** of treatment for metformin arm vs placebo arm: 20.5 vs 21.5 days, respectively.
- primary outcome:** immunohistochemical expression of Ki-67

# Results

---

- Nausea, vomiting, diarrhoea and anorexia significantly higher in metformin arm
- Metformin treatment had no effect on Ki-67 expression
- Women with a BMI  $<30$  kg/m<sup>2</sup> had higher decrease in Ki-67 expression than the placebo group (8.3% vs 5.5%)

# Conclusions

---


- There is no overall reduction in endometrial cancer cell proliferation with short term metformin treatment.
- Patients with a BMI  $<30 \text{ kg/m}^2$  may have a beneficial effect.

# **Cisplatin Chemo-Radiations Versus Radiation in FIGO Stage IIIB Squamous Cell Carcinoma of The Uterine Cervix – A Phase III Randomised Trial**


U. Mahantshetty et al.

**ESGO7-1305**

# Introduction –what we know?



Radiotherapy + Chemotherapy



Radiotherapy +/- Chmotherapy?


# Objectives & Methods

## Objectives


- To evaluate the role of concomitant chemo-radiation (CHRT) versus radiation (RTH) in FIGO stage IIIB squamous cell cervical carcinoma.

## Methods

- Accrual period; 7/2003 – 9/2011 ; median follow-up: 88 months (61-113)
- >90% treatment compliance




# Results



## Disease-free survival at 5 years

- Chemo-radiation arm: 52.3% (95% CI, 52.25 – 52.35)
- Radiation Arm: 43.8 % (95% CI, 43.75 – 43.85)



## Overall survival at 5 years

- Chemo-radiation arm: 54% (95% CI, 53.95 – 54.05)
- Radiation Arm: 46% (95% CI, 45.95 – 46.05)

Acute gastrointestinal, late recto-sigmoid and hematological complications: CHRHH > RTH

# Conclusions

---

- Concomitant weekly cisplatin based chemo-radiation should be the standard of care in FIGO stage IIIB squamous cell cervical carcinoma (absolute benefit of 8.5 % in DFS and 8% in OS).




# Prognostic Value of Lymph Node Ratio and Number of Positive Inguinal Nodes in Patients with Vulvar Cancer


S. Polterauer et al.

ESGO7-0962

# Introduction –what we know?



Survival by positive lymph nodes



N (-) 70-95%

N (+) 25-41%

GOG 37: Adjuvant radiation should be recommended for patients with two or more groin node metastases, extracapsular metastatic spread or large metastases.

Homesley HD et al. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. *Obstet Gynecol.* 1986 Dec;68(6):733-40.

Beller U et al. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. *Int J Gynaecol Obstet.* 2006 Nov;95 Suppl 1:S7-27

# Objectives & Methods

## Objectives

- To estimate the prognostic significance of lymph node ratio (LNR) (LN) in vulvar cancer patients


$$\text{Lymph node ratio} = \frac{\text{No. of involved Lymph Nodes}}{\text{No. of resected Lymph Nodes}}$$

## Methods

- international multicenter retrospective study (VULCAN)
- 745 patients diagnosed with vulvar cancer treated with inguinal lymphadenectomy
- LNR was calculated and compared with clinicopathologic parameters
- stratification of patients according to LNR ratio risk groups

# Results

- high LNR was associated with larger tumor size and higher tumor grade
- patients with LNRs 0% (N0), >0<20%, and >20% had 5-year overall survival (OS) rates of 90.9%, 70.7%, and 61.8%, respectively
- LNR and FIGO stage were associated with OS
- patients with a LNR>20% but not LNR > 0< 20% benefit from adjuvant radiotherapy



# Conclusions

---



- LNR is an independent prognostic parameter in vulvar cancer.
- LNR allows for more accurate prognostic stratification of patients than number of positive nodes.
- LNR seems useful to select appropriate candidates for adjuvant radiation.

# **LION – Lymphadenectomy in Ovarian Neoplasms. A Prospective Randomized Ago Study Group Led Gynecologic Cancer Intergroup Trial**

D. Lorusso et al.

**ESGO7-0843**

# Introduction –what we know?



Surgery is the main treatment

The aim of (debulking) surgery is to leave behind no visible cancer

**but....the effect of lymph node dissection in patients with advanced ovarian cancer was still unknown**


# Objectives & Methods

## Objectives

To define the role of systematic pelvic and para-aortic lymphadenectomy (LNE) in patients with advanced ovarian cancer (AOC) with macroscopic complete resection and clinically negative lymph nodes (LN)

## Methods

qualified centers (17)



pelvic/10 PA nodes)



# Results (1)

Characteristics of surgery	LNE (%)	No LNE (%)	P-value
Diaphragm stripping	173 (53.6)	196 (60.5)	
Gastrointestinal tract resection	169 (52.3)	167 (51.5)	0.84
Splenectomy	62 (19.2)	56 (17.3)	0.53
Portahepatis/lesser omentum	61 (18.9)	69 (21.3)	0.44
Complete resection	321 (99.4)	322 (99.4)	0.99

Characteristics of lymphadenectomy	LNE (%)	No LNE (%)	Difference	P-value
Resected LN total	57 (45-73)			
Para-aortic LN	22 (16-33)			
Pelvic LN	35 (26-43)			
Lymph node metastases	180 (55.7)			
Duration [min]	340 (270-420)	280 (210-360)	+1 hour	<0.001
Intensive Care Unit	250 (77.6)	223 (69.4)	+8%	0.01

## Results (2)

---

- post-op platinum-taxane based chemotherapy was given in 85% of the patients in the no-LNE arm and 80% in the LNE arm
- median PFS 26 months in both arms (HR 1.11, 95%CI 0.92-1.34 p=0.30)

# Conclusions

---



- LION study data do not support systematic LNE of clinically negative LN in patients with AOC receiving macroscopic complete resection.
- LNE of clinical negative LN in patients with AOC and complete resection should be omitted.

# Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Ovarian Cancer

W.J. Van Driel et al.

**ESGO7-1447**

# Introduction –what we know?




Hyperthermic intraperitoneal **chemotherapy** (HIPEC) is a highly concentrated, heated **chemotherapy treatment** that is delivered directly to the abdomen during **surgery**. Unlike **systemic chemotherapy** delivery, which circulates throughout the body, HIPEC delivers **chemotherapy** directly to **cancer** cells in the abdomen

# Objectives & Methods

## Objectives

- To assess whether the addition of HIPEC to interval debulking surgery (IDS) would improve outcome among patients with stage III epithelial ovarian cancer (EOC); to assess safety profile and Quality of life (QoL)



## Methods



*HIPEC: open technique, 40-41°C, 90 minutes perfusion, cisplatinum 100 mg/mq, sodium thiosulfate IV to protect renal function*

# Results (1)


- efficacy (RFS and Median OS)




0% 20% 40% 60% 80%

# Results (2)

- most common adverse events



- health related Quality of Life





# Conclusions

---

- Adding HIPEC to complete or optimal IDS for FIGO stage III ovarian cancer prolongs RFS and 5yr OS, with no severe toxicity or worsening of QoL.

# **Oncological Management and Pregnancy Outcomes in Women Diagnosed with Cancer During Pregnancy: A 20-Year International Cohort Study of 1170 Patients**

De Haan et al.

**ESGO7-1472**

# Introduction – what we know?

## International network

### Australia:

Rhonda FARI  
Oncology M.

### Canada:

Elena REYDI  
Follow-up P  
Ellen WARNI  
Medical Onc

### France:

Martin KOSKAS, *Hôpital Bichat – Claude-Bernard, Dept. Gynecology*

### Kazakhstan:

Roman ROU  
Dept. Gynéc Paris, France  
Gabit OLENBAY, *National Centre for Neurosurgery, Dept. Pediatric Neurosurgery, Astana, Kazakhstan*

### Lithuania:

Cathérine U.  
de la chirurgi

### Austria:

Christoph BE  
und Geburts.  
Austria

Philipp KLAR  
Geburtshilfe,  
Vesna BJELI  
und Geburts.  
Austria

### Chile:

Fernando HI  
Facultad de

### Czech Republ Austria

Uwe LANG, I  
Gynecology,  
Stephan POL  
Gynaecologi

Michael HAL  
Medical Fac  
Kralovske V.  
David CIBUL  
Faculty of M  
University H

### Germany:

Dominik DEI  
Germany

### Mexico:

Wolfgang JA  
Gynecology,  
Annette HAS  
of Obstetrics  
Anna KACZE  
of Obstetrics

Alvaro CAB  
of Ixtapalu  
oncology di  
Ixtapaluca,

### Norway:

Rainer KIMM  
Gynecology,  
Mandy MAN  
Platz, Dept.  
Ines SCHOE  
University H

Line BJORG  
Obstetrics i  
Kristina LIN  
University I  
Cancer, Osl

### Finland:

Nanna SAR  
Biomedicum

### Poland:

Lucie SEDLA  
Obstetrics, I  
Roxana SCH  
Obstetrics &  
Sabine SEIL  
Gynecology,

Hanne STEI  
population-

Marta BALA  
(Jagiellonia  
Krakow, Po  
Wojciech Ki

### United Kingdom:

Adrius GAU  
of Gynecol  
Daiva VAITI  
Gynecologi

Gianfilippo BERTELLI, *Sussex Cancer Center, Brighton, UK*  
Shiroma DA SILVA, *Oxford University Hospitals NHS Trust, Dept. of Oncology, Oxford, UK*

Susan CLEATOR, *St Mary's and Charing Cross Hospitals, Imperial Healthcare NHS Trust, London, UK*  
Siân E TAYLOR, *Liverpool Women's Hospital, Dept. of Gynaecological Oncology, Liverpool, UK*

Nicholas REED, *Beatson Oncology Center, Gartnavel General Hospital, Glasgow, UK*

Susan ROBINSON, *Guy's and St Thomas' NHS Foundation Trust, Haematology Dept., London, UK*

Pete WALLROTH, *Mummy's Star, UK & Ireland*

### United States of America:

Elyce CARDONICK, *Rowan University, Division of Maternal-Fetal Medicine, Dept. Obstetrics & Gynecology, Camden NJ, USA*

Andrew EVENS, *Rutgers Cancer Institute of New Jersey, USA*

Amer KARAM, *Stanford Hospital and Clinics, Division of Gynaecological Oncology, Stanford, USA*

Kimberly MA, *University of Washington, Division of Maternal-Fetal Medicine, Dept. Obstetrics & Gynecology, Washington, USA*

### Uruguay

Santiago SCASSO, *Pereira Rossell Hospital, Dept. Obstetrics & Gynecology, Montevideo, Uruguay*



[Registration tool](#)

CANCER IN PREGNANCY FOUNDATION NEWS & EVENTS PARTNERS PATIENTS CONTACT



ch  
track  
onials

## Cancer in pregnancy

For nearly a decade, we have been leading an innovative research project on the treatment of cancer in pregnant women. Our research team studies the effects of various cancer therapies on the health of

### News

- The European Research Council supports our research
- More than 2000 registrations in our international registry!
- New article in Placenta -

# Objectives & Methods

## Objectives

- To analyze the oncological management and the obstetrical and neonatal outcomes of patients treated in the last 20 years by members of the INCIP

## Methods


Data on oncological, obstetrical and neonatal outcome for patients diagnosed between 1996 and 2016 with primary cancer during pregnancy selected from the INCIP online registration database.

Primary outcome measures:

- Preterm pre-labour ruptur of membranes (PPROM) and/or preterm contractions.
- Small-for-gestational-age (SGA).
- Neonatal intensive care unit (NICU) admission.
- Changes in oncological management over 20 years
- Changes in obstetrical management over 20 years

# Results (1)

- 1170 patients / 37 centers / 16 countries, including 955 live births
- Every five years:
  - 10% more patients were treated during pregnancy (31% more received chemotherapy)
  - 4% more live births, 7% fewer preterm live births, 9% less iatrogenic preterm deliveries



## Results (2)

- Congenital malformations occurred in 4% of newborns (2% minor and 2 % major malformations)
- Odds ratio of chemotherapy exposure was:
  - 2.02 (95% CI 1.19 to 3.40), for preterm pre-labour ruptur of membranes and/or contractions
  - 2.37 (95% CI 1.31-4.28) for NICU admission
  - 1.83 (95% CI 1.21 to 2.78) for small-for-gestational-age (mainly platinum-based and alkylating chemotherapy appeared to increase the incidence).

# Conclusions

---

- The referral of pregnant cancer patients who need chemotherapeutic treatment to centers with obstetrical high care units is recommended.

# Acknowledgements

This 'Best of ESGO' presentation was prepared by members of ENYGO (European Network of Young Gynae Oncologists)

**Kamil Zalewski, Poland**

**Elisa Piovano, Italy**

**Zoia Razumova, Sweden**

**Ilker Selcuk, Turkey**

**Tanja Nikolova, Republic of Macedonia**

under the leadership of Professors **Cristiana Sessa**, Switzerland, **Carien Creutzberg**, the Netherlands and **Denis Querleu**, France for ESGO members who might not attend the ESGO2017 congress or missed some oral presentations.





**ESGO** ♀ **20**

INTERNATIONAL MEETING OF  
THE EUROPEAN SOCIETY OF  
GYNAECOLOGICAL ONCOLOGY (ESGO)

NOVEMBER 04-07, 2017 | VIENNA, AUSTRIA

*European Gynaecological Oncology Congress 2017*

Thank you!